Does Centene Corporation Cover Metformin?

What Is Centene Corporation and Which Plans Does It Run?

Centene Corporation is one of the largest managed-care organizations in the United States, serving roughly 28 million members across all 50 states as of 2024. It operates through state-specific subsidiaries rather than a single national plan, which is the main reason coverage rules differ by geography.

The major subsidiaries include:

• Ambetter (ACA Marketplace plans in more than 30 states)
• WellCare (Medicare Advantage and Medicaid in multiple states)
• Sunshine Health (Medicaid and CHIP in Florida)
• Peach State Health Management (Georgia Medicaid)
• Buckeye Health Plan (Ohio Medicaid)
• Superior HealthPlan (Texas Medicaid and CHIP)
• Allwell (Medicare Advantage)
• Celtic Insurance (ACA Marketplace in select states)

Each subsidiary files its own formulary with its state Medicaid agency or CMS. This means a WellCare Ohio Medicaid member and an Ambetter Texas Marketplace member will have different formulary documents, different tier structures, and potentially different cost-sharing for the same metformin tablet. The shared fact is that generic metformin hydrochloride, listed on the FDA Orange Book as therapeutically equivalent to Glucophage, appears on virtually every Centene subsidiary formulary because it is inexpensive, off-patent, and recommended as first-line therapy by every major diabetes guideline. [1]

Is Metformin a Tier 1 Drug on Centene Formularies?

Generic metformin is placed at Tier 1 (preferred generic) on the overwhelming majority of Centene subsidiary formularies. Tier 1 status means the lowest member cost-sharing, which under Medicaid is often $0 or a nominal $1 to $3 copay per 30-day supply.

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes states: "Metformin remains the preferred initial pharmacological agent for the treatment of type 2 diabetes." [2] That guideline status gives payers every financial incentive to keep the drug at Tier 1, because placing a first-line, off-patent drug at a higher tier invites regulatory scrutiny and member complaints.

Under Medicare Part D, the CMS Low Income Subsidy (LIS) program caps copays for generic drugs at $4.50 for full-subsidy recipients in 2024. [3] WellCare Medicare Advantage plans, as a Centene subsidiary, must comply with these Part D rules, so metformin copays for low-income Medicare members are at or below this cap. Members without LIS typically pay $0 to $10 per fill at preferred network pharmacies under WellCare's PDP or MA-PD plans, depending on which plan they selected during open enrollment.

For Ambetter Marketplace plans, metformin is generally Tier 1 with a $0 to $15 copay after deductible on Silver and Gold plans. Bronze plans may apply the deductible before drug benefits begin, though many Ambetter Bronze plans carve out preventive generics (including metformin) from the deductible consistent with ACA preventive-care requirements. [4]

Does Centene Require Prior Authorization for Metformin?

Standard immediate-release generic metformin tablets (500 mg, 850 mg, 1 to 000 mg) do not require prior authorization on Centene formularies. This is consistent across Medicaid, Medicare Advantage, and Marketplace lines because the drug is generic, inexpensive, and guideline-recommended. [2]

Extended-release formulations are a different story. Generic metformin ER is usually covered at Tier 1 or Tier 2 without PA. The brand-name extended-release products, Glumetza and Fortamet, almost always require prior authorization and step-therapy documentation showing the member tried generic metformin ER first. Physicians prescribing brand extended-release should anticipate a PA request and prepare chart notes documenting intolerance to immediate-release formulations (typically gastrointestinal side effects, which affect roughly 25% of patients initiating therapy). [5]

If a PA is denied, the appeals process under Medicaid managed care is governed by federal Medicaid rules at 42 CFR §438.400, which guarantee an internal appeal within 30 days and an expedited appeal within 72 hours for urgent cases. [6] Medicare Advantage PA denials are subject to CMS appeals rules, including the right to an Independent Review Entity (IRE) review. [7]

What Does the Clinical Evidence Say About Metformin's Value?

Metformin's coverage priority is not arbitrary. The evidence supporting its use in type 2 diabetes spans more than 25 years of randomized data.

The UK Prospective Diabetes Study 34 (UKPDS 34, N=1,704 overweight patients with newly diagnosed type 2 diabetes) showed that intensive metformin therapy reduced the risk of any diabetes-related endpoint by 32% and myocardial infarction by 39% compared with conventional diet therapy, at P<0.01 for both outcomes. [8] These cardiovascular findings distinguished metformin from sulfonylureas in the same trial era and cemented its first-line status.

A 2012 Cochrane systematic review of metformin monotherapy in type 2 diabetes concluded that it lowered HbA1c by approximately 1.0 to 1.5 percentage points compared with placebo, with no significant increase in hypoglycemia risk. [9] That hypoglycemia profile is one reason payers, employers, and clinicians prefer it as an initial agent over sulfonylureas.

Metformin also produces modest weight neutrality or mild weight reduction of 1 to 3 kg over 6 months, [10] which is clinically relevant given that roughly 89% of adults with type 2 diabetes have overweight or obesity. [11]

The Diabetes Prevention Program (DPP, N=3,234) found that metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 31% over 2.8 years compared with placebo. [12] The DPP Outcomes Study (DPPOS) extended follow-up to 15 years and found that metformin continued to reduce diabetes incidence by 18% in the intention-to-treat analysis. [13]

These data matter for coverage decisions because Medicaid and Medicare plans face quality metrics tied to diabetes prevention and control (HEDIS measures), and metformin is one of the few generic medications with both an efficacy and a cost-effectiveness profile that makes coverage at Tier 1 straightforward. [14]

Metformin and Longevity Research: Why Non-Diabetics Are Asking About Coverage

A growing number of people without diabetes are asking whether their Centene plan covers metformin prescribed for longevity or anti-aging purposes. This question arises from preclinical and epidemiological data suggesting metformin may slow aging-related biological processes through AMPK activation and mTOR inhibition. [15]

The Targeting Aging with Metformin (TAME) trial (NCT03077244) is a randomized, placebo-controlled study funded by the American Federation for Aging Research, enrolling approximately 3,000 adults aged 65 to 79 who do not have diabetes or a prior cancer diagnosis. TAME aims to determine whether metformin 1 to 500 mg daily delays the onset of age-related diseases including cardiovascular disease, dementia, and cancer. Results are expected in the late 2020s. [16]

Several observational studies have suggested that diabetic patients on metformin outlive matched non-diabetic controls not on the drug, though this finding may reflect confounding. [17] A 2014 study published in Diabetes, Obesity and Metabolism (Bannister et al., N=78,241 metformin-treated patients vs. 12,222 sulfonylurea-treated and 8,494 matched non-diabetic controls) reported that metformin-treated patients had longer survival than sulfonylurea-treated patients and even longer survival than non-diabetic controls, though the authors cautioned about residual confounding. [17]

For Centene members prescribed metformin off-label for longevity, coverage is not guaranteed. Medicaid programs generally restrict coverage to FDA-approved indications, which currently include only type 2 diabetes management and, in some state Medicaid policies, prediabetes when documented by HbA1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL. [18] Medicare Advantage plans follow similar CMS restrictions. Ambetter Marketplace plans may have more flexibility but typically follow the same indication-based coverage rules. A prescribing physician documenting a diagnosis of prediabetes (ICD-10 code R73.09) may reveal coverage under many Centene subsidiaries even if the underlying motivation is disease prevention. Confirm this with the plan before prescribing.

How Centene Metformin Coverage Compares to GLP-1 Coverage

The contrast between metformin and GLP-1 receptor agonist coverage on Centene formularies is stark.

Semaglutide (Ozempic for diabetes, Wegovy for obesity) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity) typically require prior authorization, step therapy, BMI documentation, and sometimes a comorbidity qualifier on Centene plans. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks vs. 2.4% with placebo (P<0.001). [19] Despite this efficacy, Wegovy's list price exceeds $1,300 per month, and most Medicaid programs, including Centene subsidiaries, do not cover semaglutide for obesity alone as of 2025, though several states have begun expanding coverage. [20]

Metformin costs $4 to $15 for a 90-day supply at major pharmacy chains with or without insurance. The cost differential is roughly 200-fold. For patients who need weight management alongside glucose control, a common clinical approach is to start metformin for glycemic benefit and then pursue PA for a GLP-1 agent as a second agent if HbA1c or weight targets are not met at 3 months. The ADA 2024 Standards recommend considering GLP-1 agents in patients with established cardiovascular disease, heart failure, or chronic kidney disease regardless of HbA1c level, which creates a separate coverage pathway on many Centene formularies through cardiac or renal diagnoses. [2]

Tirzepatide (Mounjaro) produced 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539, BMI >27 with at least one weight-related comorbidity), P<0.001 vs. placebo. [21] Centene subsidiary formularies for Medicare Advantage list Mounjaro under prior authorization for type 2 diabetes (ICD-10 E11.xx) but generally do not cover Zepbound for obesity alone without specific state or plan authorization as of the 2025 plan year.

How to Confirm Your Specific Centene Plan Covers Metformin

Because Centene operates through subsidiaries with individual formularies, confirming coverage takes a specific set of steps rather than a single phone call to Centene corporate.

Step 1. Identify your subsidiary. Your insurance card will name the plan (Ambetter, WellCare, Buckeye Health Plan, etc.), not "Centene Corporation."

Step 2. Go to that subsidiary's website and find the "Formulary" or "Drug List" section. Search for "metformin" by generic name. Confirm the tier and any quantity limits.

Step 3. Confirm your pharmacy is in-network. Centene subsidiaries often have preferred pharmacy networks (CVS, Walmart, Walgreens, or a subsidiary-specific preferred network) where Tier 1 copays apply. Using an out-of-network pharmacy can double or triple the copay even for a Tier 1 drug.

Step 4. If you are prescribed metformin ER or a brand formulation, call member services and ask whether a prior authorization form is needed. Get the specific prior authorization criteria in writing (CMS requires plans to post these).

Step 5. If cost remains a barrier even with Tier 1 coverage, ask your pharmacist about GoodRx or Blink Health pricing. For metformin 500 mg, 90-tablet supplies are frequently available for under $10 at major chains without using insurance at all. [22]

The FDA Orange Book entry for metformin hydrochloride tablets confirms multiple AB-rated generic manufacturers, which is why the drug remains so inexpensive. [1]

Metformin Dosing, Safety, and What Centene Formularies Actually Cover

Centene formularies cover metformin in the following forms (varies by subsidiary):

• Metformin HCl immediate-release tablets: 500 mg, 850 mg, 1 to 000 mg
• Metformin HCl extended-release tablets: 500 mg, 750 mg, 1 to 000 mg
• Metformin HCl oral solution: 500 mg/5 mL (less common; confirm per plan)

Standard dosing for type 2 diabetes begins at 500 mg once or twice daily with meals, titrated over 4 to 8 weeks to a target of 1,500 to 2 to 000 mg/day in divided doses. [5] Maximum labeled dose is 2 to 550 mg/day. The DPP used 850 mg twice daily (1 to 700 mg/day total). [12]

The FDA requires a boxed warning for metformin regarding lactic acidosis, a rare but serious complication occurring at approximately 3 cases per 100,000 person-years. [23] Renal dosing adjustments are required: metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m², and initiation is not recommended when eGFR is 30 to 45 mL/min/1.73 m². [23] These renal thresholds are embedded in most Centene PA criteria for any quantity limit exceptions.

Vitamin B12 deficiency is a less-publicized long-term risk. The DPP Outcomes Study found that 15-year metformin use was associated with a 13% absolute risk of vitamin B12 deficiency vs. 6% with placebo. [13] The ADA recommends periodic B12 monitoring for patients on long-term metformin, particularly those with peripheral neuropathy. [2] Centene formularies cover standard cyanocobalamin supplements at Tier 1 under most Medicaid plans if B12 deficiency is documented.

What Centene Members With Prediabetes Should Know

Coverage for metformin in prediabetes depends on the subsidiary and the documented diagnosis. The ADA 2024 Standards state that metformin should be considered for prediabetes prevention in patients with BMI >35 kg/m², age <60 years, or prior gestational diabetes. [2] The DPP and DPPOS trials provide the primary evidence base for this recommendation. [12][13]

Medicaid programs require ICD-10 documentation. Using code R73.09 (other abnormal glucose) or E11.65 (type 2 diabetes with hyperglycemia) where clinically appropriate is standard practice. For prediabetes specifically, R73.03 (prediabetes) is recognized by most Centene Medicaid subsidiaries. Confirm this with the subsidiary's clinical criteria document before prescribing for prevention alone.

Medicare Advantage plans, including WellCare Allwell products, may cover metformin for prediabetes if the prescribing physician documents the indication clearly. CMS guidance on Medicare diabetes prevention is evolving, and the Medicare Diabetes Prevention Program (MDPP) benefit covers structured lifestyle intervention but not metformin pharmacotherapy under current CMS rules. [24] This gap means Medicare members seeking metformin for prediabetes should discuss off-label use carefully with their prescriber and confirm coverage before filling.

For members who cannot get coverage for prediabetes indication, the cash price of metformin 500 mg, 60 tablets (30-day supply at twice daily) is approximately $4 at Walmart's $4 generic program [22] and similar at Costco and Kroger pharmacies. No prior authorization is needed for cash-pay prescriptions.

Navigating a Coverage Denial for Metformin

Denials for standard generic metformin are rare but do occur, usually due to:

1. An incorrect National Drug Code (NDC) submitted by the pharmacy
2. A quantity limit flag (some plans cap at 90 tablets per 30-day fill)
3. An administrative error in the member's eligibility file

If denied, ask the pharmacist to reprocess with a corrected NDC or days-supply entry before filing a formal appeal. Most pharmacy-level errors are resolved at the point of sale within minutes.

If a PA denial occurs for extended-release or brand formulations, the prescriber's office must submit a PA request form documenting: (a) the diagnosis (ICD-10 code), (b) the clinical reason for ER over IR (e.g., documented GI intolerance at 1 to 000 mg immediate-release twice daily), and (c) any relevant lab values (HbA1c, eGFR). The ADA's 2024 Standards note that switching patients from immediate-release to extended-release metformin can reduce GI side effects in patients who experience nausea or diarrhea. [2] That clinical note is the exact language needed in the PA letter.

Federal regulations at 42 CFR §438.408 require Medicaid managed-care organizations, including all Centene Medicaid subsidiaries, to resolve standard PA requests within 3 business days. [6] Expedited requests involving urgent clinical need must be resolved within 24 hours. If those timelines are not met, the denial is automatically invalidated and the plan must approve the request.